


ABSTRACT OF THE DISCLOSURE

This invention relates to cyclic combination therapies and regimens utilizing indoline compounds which are antagonists of the progesterone receptor and having the general structure:



5

A is O, S, or NR⁴; B is a bond or CR⁵R⁶;

R⁴, to R⁶ are H, C₁ to C₆ alkyl, C₂ to C₆ alkenyl, C₂ to C₆ alkynyl, C₃ to C₈ cycloalkyl, aryl, or heterocyclic, or R⁴ and R⁵ are fused to form a ring; R¹ is H, OH, NH₂, C₁ to C₆ alkyl, C₃ to C₆ alkenyl, alkynyl, or COR^A; R^A is as defined; R² is H, halogen, CN, NO₂, C₁ to C₆ alkyl, C₁ to C₆ alkoxy, or C₁ to C₆ aminoalkyl; R³ is a substituted benzene ring, or heteroaromatic ring, in combination with a progestational agent and/or an estrogen to treat or prevent secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, carcinomas and adenocarcinomas, and contraception, among others.

15